Tyme Technologies, Inc. (TYME)

South Africa-based digital bank Tyme has achieved unicorn status with the help of fellow FinTech Nubank. The company announced Tuesday (Dec. 17) that it had raised $250 million in a Series D funding round, bringing its value to $1.5 billion.

Brazilian digital bank Nubank said it has invested $150 million in Tyme Group, a digital bank with 15 million customers in South Africa and the Philippines, funding that will help Tyme Group finance its push into Southeast Asia and list by 2028.

SÃO PAULO--(BUSINESS WIRE)--Nubank, one of the world's largest digital financial services platforms, announces today an investment of US$150 million in Tyme Group as the lead of their series D funding round. The total investment round amounted to US$250 million, with M&G Catalyst Fund subscribing for US$50 million and existing shareholders with further US$50 million. Tyme Group is one of the fastest-growing digital banks globally, with 15 million customers and operations in South Africa and.

Wilmington, Delaware--(Newsfile Corp. - July 6, 2022) - Rigrodsky Law, P.A. is investigating Tyme Technologies, Inc. ("Tyme") (NASDAQ: TYME) regarding possible breaches of fiduciary duties and other violations of law related to Tyme's agreement to be acquired by Syros Pharmaceuticals, Inc. ("Syros") (NASDAQ: SYRS). Under the terms of the agreement, Tyme's shareholders will receive approximately 0.4312 shares of Syros common stock for each share of Tyme common stock they own.To learn more about this investigation...

NEW YORK , July 5, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS) in connection with the proposed merger of the Company with TYME Technologies, Inc. ("TYME") (NASDAQ: TYME).  Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will continue to trade publicly on the Nasdaq under the ticker symbol "SYRS.

Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million. Syros expects to issue.

CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-down and transaction expenses is currently estimated to be approximately $

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives.

Tyme Technologies Inc. TYME, -5.56% , a biotech developing cancer metabolism-based treatments, said Tuesday its board has decided to explore its strategic options and has hired Moelis & Co. as a financial adviser and Faegre Drinker Biddle & Reath LLP as its legal adviser. The move comes after the Bedminster, New Jersey-based company had to discontinue a Phase 2/3 trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for patients with metastatic pancreatic cancer after the trial sponsor terminated the study arm due to futility.

Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event. Following the Company’s presentation, there will be a Q&A session. Management will address both live questions and those submitted in advance via email to lwilson@insitecony.com. The deadline to submit questions for the conference call is 5:00 PM ET on February 7, 2022. About TYME Technologies, Inc. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to cause cancer cell death. The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline. For more information about the Company, visit www.tymeinc.com and connect on Facebook, LinkedIn, and Twitter. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 10, 2021, as well as subsequent reports and filings from time to time with the SEC. The information contained in this press release is as of the release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

The stock price of Tyme Technologies Inc (NASDAQ: TYME) fell by 1.66% in the most recent trading session. This is why it happened.

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices.

Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q2 2021 Results - Earnings Call Transcript

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the Jefferies London Healthcare Conference as follows: Date:     Wednesday, November 17, 2021       Time:     1:40 PM Greenwich Mean Time / 8:40 AM Eastern Standard Time       Webcast: